New Clinical Treatment Guideline Outlines Recommendations to Reduce Blood Clots After Hip and Knee Replacement

Guideline recommends postoperative blood thinners, compression, early mobilization to prevent clots

 

Rosemont, IL, USA (September 30, 2011) – An updated clinical practice guideline released last week by the American Academy of Orthopaedic Surgeons (AAOS) Board of Directors recommends how to reduce the likelihood of blood clots after hip or knee replacement surgery, procedures that more than 800,000 Americans undergo each year. The new guideline suggests use of preventive treatments and advises against routinely screening patients after surgery using ultrasound imaging.

 

“Hip and knee arthroplasty [joint replacement surgery] is among the most successful of procedures in terms of restoring function and minimizing pain. However, one possible complication that orthopaedic surgeons are concerned about is venous thromboembolic disease,” said Joshua Jacobs, MD, Academy second vice president, an orthopaedic surgeon at Rush University Medical Center in Chicago, who was chairman of the workgroup that developed the guideline.

 

Thromboembolic disease encompasses two conditions: deep vein thrombosis (DVT), or formation of a blood clot in a deep vein such as in the thigh or calf, and pulmonary embolism (PE). In the relatively uncommon event of a PE, pieces of a clot break free and travel through the vein to the lung, where they can lodge in an artery. PE typically causes no symptoms, however possible symptoms include shortness of breath, chest pain, light headedness or chest congestion. In very rare cases, PE can be fatal. Likewise, in many patients, DVT causes no symptoms. However, in some patients, DVT can lead to symptoms such as leg swelling and pain that can necessitate further treatment or rehospitalization. The goal of the orthopaedic surgeon is to prevent, as much as possible, the occurrence of PE and DVT following total hip and knee replacement.

 

According to the guideline, in the absence of prophylaxis, DVT occurs in about 37 percent of patients, as detected by imaging. The majority of those patients will remain asymptomatic and will require no further treatment. Recent studies in Denmark show that only 0.7 percent of hip replacement patients and 0.9 percent of knee replacement patients require hospitalization because of DVT in the first three months after surgery.

 

“After looking at all available scientific research evidence, in a rigorous fashion to minimize bias, we made recommendations that can help guide practitioners in the safest and most effective ways to prevent this potentially serious complication,” said Jacobs.

 

Among the preventive measures the experts analyzed for safety and effectiveness are mechanical compression devices, designed to improve blood flow in the legs after surgery, as well as drug therapy. Drug therapy involves anticoagulants, commonly called blood thinners, as well as aspirin, which interferes with blood clotting by acting on platelets.

 

The work group also outlined suggestions for future research to fill in the evidence gaps that were apparent through an exhaustive and systematic review of the medical literature. Further research is deemed critical to develop the optimum strategies to prevent venous thromboembolic disease in the safest and most effective manner.

 

From the evidence reviewed, the workgroup made the following recommendations for physicians treating patients before hip or knee replacement:

 

  • Patients should stop taking antiplatelet medications (a type of anticoagulant), such as aspirin and clopidogrel (Plavix), because of the increased risk of blood loss during surgery with these drugs.
  • A patient should discuss the timing of stopping any medication with his or her physician.
  • A prior DVT or PE is an additional risk factor for thromboembolic disease and it is important that patients discuss any such event with his or her surgeon. There is insufficient evidence to recommend for or against routinely assessing patients for other possible risk factors.
  • Patients may want to have the surgery performed under regional anesthesia, such as epidural or spinal, rather than general anesthesia. Although evidence suggests that these regional approaches do not affect the occurrence of DVT or PE, they do limit blood loss.

 

The workgroup also made these recommendations for care after hip or knee replacement:

 

  • Hip and knee replacement patients should not have routine postoperative screening for thromboembolic disease with duplex ultrasonography (an ultrasound test that shows how blood moves through the arteries and veins). Screening with this test does not significantly reduce the rate of symptomatic DVT or PE or the rate of fatal PE.
  • Patients should receive anticoagulant therapy (unless they have a medical reason for not being able to use these drugs, such as a bleeding disorder or active liver disease) and/or mechanical compression devices after a hip or knee replacement surgery. There is, however, insufficient evidence to recommend any particular preventive strategy or the duration of these treatments. Patients should discuss the duration and type of preventive treatment with their physician.
  • After hip or knee replacement, patients should get up and walk as soon as safely possible. Although there is insufficient evidence that “early mobilization” reduces DVT rates, early mobilization is low cost, of minimal risk and consistent with current practice.

 

The full guideline, “Preventing Venous Thromboembolic Disease in Patients Undergoing Elective Hip and Knee Arthroplasty,” along with all supporting documentation and workgroup disclosures, is available on the AAOS website: www.aaos.org/guidelines

 

More information about DVT, and its symptoms, is available at www.orthoinfo.org

 

 

Disclaimer: This Clinical Practice Guideline is not intended to be a fixed protocol, as some patients may require more or less treatment or different means of diagnosis. Clinical patients may not necessarily be the same as those found in a clinical trial. Patient care and treatment should always be based on a clinician’s independent

 

 


American Academy of Orthopaedic Surgeons, 30.09.2011 (tB).

MEDICAL NEWS

Inadequate sequencing of SARS-CoV-2 variants impedes global response to COVID-19
New meta-analysis finds cannabis may be linked to development of…
New guidance on how to diagnosis and manage osteoporosis in…
Starting the day off with chocolate could have unexpected benefits
Better mental health supports for nurses needed, study finds

SCHMERZ PAINCARE

Versorgung verbessern: Deutsche Gesellschaft für Schmerzmedizin fordert die Einführung des…
Pflegeexpertise im Fokus: Schmerzmanagement nach Operationen
Versorgung verbessern: Bundesweite Initiative der Deutschen Gesellschaft für Schmerzmedizin zu…
Jedes vierte Kind wünscht bessere Schmerzbehandlung
Lebensqualität von Patienten in der dauerhaften Schmerztherapie mit Opioiden verbessern

DIABETES

Bundestag berät über DMP Adipositas: DDG begrüßt dies als Teil…
Mit der Smartwatch Insulinbildung steuern
Verbände fordern bessere Ausbildung und Honorierung von Pflegekräften für Menschen…
Minimalinvasive Geräte warnen ungenügend vor Unterzuckerung
Typ-1-Diabetes und Hashimoto-Thyreoiditis treten häufig gemeinsam auf

ERNÄHRUNG

Wie eine Diät die Darmflora beeinflusst: Krankenhauskeim spielt wichtige Rolle…
DGEM plädiert für Screening und frühzeitige Aufbautherapie: Stationäre COVID-19-Patienten oft…
Führt eine vegane Ernährungsweise zu einer geringeren Knochengesundheit?
Regelmässiger Koffeinkonsum verändert Hirnstrukturen
Corona-Erkrankung: Fehl- und Mangelernährung sind unterschätze Risikofaktoren

ONKOLOGIE

Anti-Myelom-Therapie mit zusätzlich Daratumumab noch effektiver
Positive Ergebnisse beim fortgeschrittenen Prostatakarzinom: Phase-III-Studie zur Radioligandentherapie mit 177Lu-PSMA-617
Lymphom-News vom EHA2021 Virtual. Alle Berichte sind nun online verfügbar!
Deutsch-dänisches Interreg-Projekt: Grenzübergreifende Fortbildungskurse in der onkologischen Pflege
Sotorasib: Neues Medikament macht Lungenkrebs-Patienten Hoffnung

MULTIPLE SKLEROSE

NMOSD-Erkrankungen: Zulassung von Satralizumab zur Behandlung von Jugendlichen und Erwachsenen
Verzögerte Verfügbarkeit von Ofatumumab (Kesimpta®)
Neuer Biomarker bei Multipler Sklerose ermöglicht frühe Risikoeinschätzung und gezielte…
Multiple Sklerose beginnt oft lange vor der Diagnose
Goldstandard für Versorgung bei Multipler Sklerose

PARKINSON

Meilenstein in der Parkinson-Frühdiagnose
Parkinson-Erkrankte besonders stark von Covid-19 betroffen
Gangstörungen durch Kleinhirnschädigung beim atypischen Parkinson-Syndrom
Parkinson-Agenda 2030: Die kommenden 10 Jahre sind für die therapeutische…
Gemeinsam gegen Parkinson: bessere Therapie durch multidisziplinäre Versorgung